Navigation Links
Watson Announces Favorable District Court Ruling in Generic Fentora® Patent Suit
Date:3/14/2011

MORRISTOWN, N.J., March 14, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced that the United States District Court for the District of Delaware has ruled that Watson's generic version of Fentora® (fentanyl buccal tablets C-II) does not infringe United States Patent Nos. 6,200,604 or 6,974,590 (the '604 and '590 Patents) and that the '604 and '590 Patents are invalid.  A decision on United States Patent No. 6,264,981 remains outstanding and Watson remains enjoined from launching its generic version of Fentora®.  Watson's Abbreviated New Drug Application for its generic version of Fentora® has been approved by the FDA.  

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is a leading integrated global specialty pharmaceutical company.  The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release.  It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing and outcome of the pending patent litigation and risks that an adverse outcome in such litigation could render Watson liable for substantial damages; the difficulty of predicting the timing and outcome of any appeal of the pending patent litigation; the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31,2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

Fentora® is a registered trademark of Cima Labs, Inc., a subsidiary of Cephalon, Inc.

(Logo: https://photos.prnewswire.com/prnh/20100121/LA41294LOGO)CONTACTS:Investors:Patty EisenhaurWatson Pharmaceuticals, Inc. (973) 355-8141Media:Charlie MayrWatson Pharmaceuticals, Inc. (973) 355-8483
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Promotes David Buchen, R. Todd Joyce to Executive Vice President
2. Watson to Present at the Barclays 2011 Global Healthcare Conference
3. Watson to Present at the Cowen & Company 31st Annual Healthcare Conference
4. Watson to Present at the 2011 Citi Global Healthcare Conference
5. Watson Fourth Quarter 2010 Net Revenue Increases 21% to $953 Million
6. Watson Announces Favorable District Court Ruling in Generic Mucinex® Patent Suit
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2010 Earnings
8. Watson Confirms Welchol® Oral Suspension Patent Challenge
9. Watson Presents Outlook for Continued Long Term Growth
10. Reportlinker Adds Watson Pharmaceuticals Inc.: PharmaVitae Profile
11. Watson Announces Preliminary Financial Performance for FY 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2017)... July 31, 2017 7D Surgical, developer of ground ... purchased the 7D Surgical System to support its strategic sales ... D.C. and Virginia.  7D Surgical has entered into ... of the premier medical facilities within those markets. ... ...
(Date:7/28/2017)... --EnvoyHealth, a Diplomat company, has partnered with Compliance Meds ... a technology designed to improve patient medication adherence. ... solutions and services that help track and improve patients, ... LITE offers medication monitoring and control for patients and ... Records date and time of bottle ...
(Date:7/27/2017)... Pa., July 27, 2017  West Pharmaceutical Services, Inc. ... results for the second-quarter 2017 and updated financial guidance ... Second-Quarter 2017 Highlights Reported net ... over the prior-year quarter. Net sales at constant currency ... reported-diluted EPS was $0.51, compared to $0.60 in the ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... ... Pastor and Overseer at The House of Yahweh in Abilene, Texas, has released a new ... the mother of the Savior whom the world calls “Mother Mary”. Yisrayl says when compared ... of this historical woman. , “The world bows, kisses the feet of, cries out ...
(Date:8/18/2017)... CARMEL, IN (PRWEB) , ... August 18, 2017 , ... ... 36th annual list, the most prestigious ranking of the nation's fastest-growing private companies. This ... in the exclusive Inc. 5000 ranking . This year’s ranking reflects ASH’s 76 ...
(Date:8/18/2017)... ... 18, 2017 , ... “Our Mountains to Climb: A Journey of Love and ... stronger together through the faith they shared to overcome struggles in life. “Our Mountains ... published author, Barbara J. Corcoran, a retired teacher and happily married since 1999; the ...
(Date:8/18/2017)... ... ... “Three Narrow Roads”: a vivid and provocative look into the narrow path toward ... Sr., is currently the pastor-teacher-visionary at Simply the WORD Church, a global prayer ministry ... program geared towards youth. , King shares, “When I take time to think about ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Depressed: Super Heroes of the Bible”: ... reflect upon the stories and the relevance these tales may have on the reader’s ... Linhart, a former special education teacher, Jessica spends much of her time enjoying nature ...
Breaking Medicine News(10 mins):